Theorem Clinical Research

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Treeway, LACDR collaborate on ALS therapy development

Thursday, October 16, 2014 02:36 PM

Treeway, a Netherlands-based, amyotrophic lateral sclerosis (ALS) R&D strategy-focused company, and the Leiden Academic Center for Drug Research (LACDR) at the University of Leiden, the Netherlands, have formed a collaboration focused on the optimization of clinical trial designs and data analysis for ALS through the use of population disease progression models. Both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and test the effect of interventions in the different identified pathways.

More... »


Servier Canada opens Clinical Development Center in Montreal

Thursday, October 16, 2014 02:34 PM

Servier Canada, the Canadian subsidiary of Servier, has opened its new Clinical Development Center in Montreal.

More... »


Report: metastatic breast cancer research underfunded

Thursday, October 16, 2014 02:32 PM

While metastatic breast cancer (MBC) claims the lives of 40,000 women and men in America every year and 20-30% of those diagnosed with early stage breast cancer will go on to develop recurrent, metastatic disease, awareness remains low and only 7.1% of breast cancer research investments over the last dozen years were focused on MBC, according to MBC Alliance’s report Changing the Landscape for People Living with Metastatic Breast Cancer.

More... »

Moderna, Karolinska Institute to collaborate on messenger RNA therapeutics

Thursday, October 16, 2014 02:30 PM

Moderna Therapeutics, a Cambridge, Mass.-based pharma, has formed a strategic, long-term collaboration with Karolinska Institute (KI) and Karolinska University Hospital (KUH), both in Sweden, for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics enable the in vivo production of both intracellular proteins and secreted proteins.

More... »

NIH awards $15.6 million for pulmonary research program

Thursday, October 16, 2014 02:29 PM

The NIH has awarded up to $15.6 million in grants over five years to the University of North Carolina, Chapel Hill (UNC-CH) and the University of Colorado, Denver (UCD) to conduct research with mucolytic agents discovered by Parion Sciences, a Durham, N.C.-based company focused on pulmonary and ocular diseases, and to enable Investigational New Drug applications for Parion's molecules.

More... »

New U.K. health campaign urges people with diabetes to 'TALK Hypos'

Thursday, October 16, 2014 02:27 PM

The TALK Hypos awareness campaign has launched in the U.K., supported by Novo Nordisk and Diabetes U.K., encouraging people with diabetes to report hypoglycemia (hypos) to their doctor or nurse.

More... »

West Pharmaceutical Services, HealthPrize Technologies to reward patient adherence

Thursday, October 16, 2014 02:26 PM

West Pharmaceutical Services and HealthPrize Technologies are teaming up to reward patients for taking their medications.

More... »

Inversion rule change prompts AbbVie to halt Shire takeover

Thursday, October 16, 2014 02:21 PM

In what could have been a major pharmaceutical acquisition and one of the biggest tax inversion deals, Chicago-based AbbVie has recommended its shareholders vote against its proposed $54 billion takeover of Shire, a Dublin-headquartered pharmaceutical company specializing in medications to treat attention deficit disorder and rare diseases

More... »

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Thursday, October 16, 2014 12:29 PM

Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company's statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).

More... »

CytRx appoints Steven A. Kriegsman as chairman of the board

Thursday, October 16, 2014 12:21 PM

CytRx, a biopharmaceutical R&D company specializing in oncology, has appointed Steven A. Kriegsman, president, CEO and a director of the company, as chairman of the board, effective Oct. 15. He replaces Max E. Link, Ph.D., whose unexpected passing was announced on Oct. 7.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs